These include monoclonal antibody inhibitors such as MA-TCK26D6, which specifically inhibits plasmin-mediated activation of TAFI, and has been shown to reduce thromboembolism in-vivo in a murine model [17], and, in a diabody confirmation with a plasminogen-activator inhibitor-1 (PAI-1) antibody, effectively reduced lesion size and improved functional outcomes in a stroke model [18]. This evidence concerns the gene SERPINE1 and Stroke.